TIGIT and neoplasm: In addition, clinical and basic studies have reported the anti-tumor responses of immunotherapy against CD155 (12), TIGIT (13), CD96 (14) and CD226 (15), and elucidated the potential of modulating the CD155-TIGIT/CD96/CD226 immune pathway to enhance the anti-tumor immune response.